Federal Register / Vol. 63, No. 78 /Thursday, April 23, 1998 / Notices 20203

restrictions on the extent to which a

CDC-funded awardee can participate in

or implement environmental changes

within their respective communities.

(See Section: Use of Funds.)

Potential applicants may obtain a

copy of Healthy People 2000 (Full

Report, Stock Number 017–001–00474–

0), or Healthy People 2000 (Summary

Report, Stock Number 017–001–00473–

1), referenced in the Introduction

through the Superintendent of

Documents, Government Printing

Office, Washington, DC 20402–9325;

telephone (202) 512–1800.

Dated: April 17, 1998.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 98–10788 Filed 4–22–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0531]

Agency Information Collection

Activities; Announcement of OMB

Approval

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘Performance Standard for Electrode

Lead Wires and Patient Cables: Petitions

for Exemptions and Variances’’ has been

approved by the Office of Management

and Budget (OMB) under the Paperwork

Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT:

Margaret R. Schlosburg, Office of

Information Resources Management

(HFA–250), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the

Federal Register of January 21, 1998 (63

FR 3141), the agency announced that

the proposed information collection had

been submitted to OMB for review and

clearance under section 3507 of the PRA

(44 U.S.C. 3507). An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a

currently valid OMB control number.

OMB has now approved the information

collection and has assigned OMB

control number 0910–0367. The

approval expires on April 30, 2001.

Dated: April 16, 1998.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 98–10778 Filed 4–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0485]

Agency Information Collection

Activities; Announcement of OMB

Approval

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘Shipment of a Blood Product Prior to

Completion of Testing for Hepatitis B

Surface Antigen (HbsAg), and Shipment

of Blood Products Known Reactive for

HbsAg’’ has been approved by the Office

of Management and Budget (OMB)

under the Paperwork Reduction Act of

1995 (the PRA).

FOR FURTHER INFORMATION CONTACT:

JonnaLynn P. Capezzuto, Office of

Information Resources Management

(HFA–250), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the

Federal Register of December 19, 1997

(62 FR 66633), the agency announced

that the proposed information collection

had been submitted to OMB for review

and clearance under section 3507 of the

PRA (44 U.S.C. 3507). An agency may

not conduct or sponsor, and a person is

not required to respond to, a collection

of information unless it displays a

currently valid OMB control number.

OMB has now approved the information

collection and has assigned OMB

control number 0910–0168. The

approval expires on April 30, 2001.

Dated: April 16, 1998.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 98–10781 Filed 4–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0046]

Comprehensive List of Current

Guidance Documents at the Food and

Drug Administration; Correction

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug

Administration (FDA) is correcting a

document that published in the Federal

Register of February 26, 1998 (63 FR

9795). The document provided a

comprehensive list of all guidance

documents currently in use at the

agency. FDA committed to publishing

this list in its February 1997 ‘‘Good

Guidance Practices’’ (GGP’s), which set

forth the agency policies and procedures

for the development, issuance, and use

of guidance documents. The document

was published with several errors. This

document corrects those errors.

DATES: General comments on this list

and on agency guidance documents are

welcome at any time.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, 12420 Parklawn Dr.,

rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Lisa

L. Barclay, Office of Policy (HF–22),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–3360.

In FR Doc. 98–4916, appearing on

page 9795, in the Federal Register of

Thursday, February 26, 1998, the

following corrections are made:

1. On page 9795, in the second

column, under the ‘‘ADDRESSES’’

caption, ‘‘(HFD–305)’’ is removed and

‘‘(HFA–305)’’ is added in its place.

2. On page 9834, in the fifth entry

entitled ‘‘Clinical Testing of Infant

Formulas with Respect to Nutritional

Suitability for Term Infants,’’ in the

second column, ‘‘1985’’ is removed and

‘‘1988’’ is added in its place.

3. On page 9834, in the first column,

the sixth entry entitled ‘‘Guidelines for

the Evaluation of the Safety and

Suitability of New Infant Formulas for

Feeding Infants with Allergic Diseases’’

is removed and ‘‘Evaluation of Safety

and Suitability of New Infant Formulas

for Feeding Preterm Infants’’ is added in

its place.

4. On page 9834, under the heading,

‘‘VI. Guidance Documents Issued by the

Center for Veterinary Medicine (CVM),’’